Norm Strickland
Immunology Business Manager, Ultra Rare Disease, Alpha-1 at Takeda Pharmaceuticals (formerly Nycomed) - Lexington, MA, US
Norm Strickland's Colleagues at Takeda Pharmaceuticals (formerly Nycomed)
Jill Staudacher
Senior Regional Business Manager - Ultra Rare Disease/Orphan Drug - Gastroenterology
Norm Strickland's Contact Details
224-554-6500
Culloden, West Virginia
Takeda Pharmaceuticals (formerly Nycomed)
Norm Strickland's Company Details
On October 1, 2011, Takeda Pharmaceutical Company Limited acquired Nycomed. Through the acquisition, Takeda, the largest pharma company in Asia, broadened its coverage of the global pharmaceutical market, especialy in Europe and emergig markets. More information on http://www.takeda.com. The below information is from before the acquisition: Nycomed is a privately owned global pharmaceutical company with a diversified portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC products completes the portfolio. Its R&D is structured around collaborations. In-licensing and expanding in emerging markets are cornerstones of the company's growth strategy. Nycomed employs 12,500 associates worldwide, and its products are sold in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US and Japan its products are available through best in class partners. Headquartered in Zurich, Switzerland, the company generated total sales of € 3.2 billion in 2010 and an adjusted EBITDA of € 851 million.